OrbusNeich Receives CE Mark Approval for Scoreflex(TM) Coronary Dilatation Catheter

Monday, June 9, 2008 General News J E 4
HONG KONG, June 9 OrbusNeich today announced that it hasreceived CE Mark approval for the Scoreflex coronary dilatation catheter.

The new product, which rounds out OrbusNeich's balloon catheter portfolio,is designed for use in focused force angioplasty, a technique in which theforce resulting from balloon inflation in a stenotic lesion is concentrated atone or more locations within the stenosis. Published research has shown thatfocused force angioplasty is effective in resolving resistant stenosis whilereducing the frequency of complications with its use of gradual, low-pressureinflations.

"Scoreflex has helped me prepare the vessel better prior to stentdeployment," said Dato' Dr. Rosli Mohd Ali, head of the Cardiology Department,National Heart Institute, Kuala Lumpur, Malaysia. "It also has the potentialto achieve good angiographic results when compared to using a regular balloonin treating bifurcation lesions and lesions affecting small vessels."

The Scoreflex dual wire system creates a focal stress pattern tofacilitate effective controlled plaque fracture at low-resolution pressure. Inaddition to its effective dilatation, Scoreflex has a low crossing profile andunbeatable trackability. OrbusNeich expects the rapid adoption and integrationof the balloon catheter into interventional cardiologists' practices.

OrbusNeich designs, develops, manufactures and markets innovative medicaldevices for the treatment of vascular diseases. The company's productportfolio includes the Genous(TM) Bio-engineered R stent(TM), anantibody-coated device that is the first-ever stent to capture a patient'sendothelial progenitor cells (EPCs) to accelerate the natural healing processfollowing placement. Other products are stents, balloons and guidingcatheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM),Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and hasoperations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; andShenzhen, China. OrbusNeich, which has provided cardiology devices tophysicians through its predecessor companies since 1979, today suppliesproducts to interventional cardiologists in more than 60 countries. For moreinformation, visit .

SOURCE OrbusNeich


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Meditation Pro Retains TransMedia Group to Publici...
Dubai Health Authority Unveils Healthcare for All